NASDAQ:IVTY - Invuity Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.39
+0.30 (1.20%)
Get New Invuity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVTY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVTY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Invuity in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.39.

This chart shows the closing price for IVTY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Invuity. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/17/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
9/12/2018SVB LeerinkDowngradeOutperform ➝ Market PerformLow
9/11/2018Stifel NicolausDowngradeBuy ➝ HoldLow
9/11/2018Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralMedium
9/11/2018William BlairDowngradeOutperform ➝ Market PerformMedium
5/4/2018Stifel NicolausLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00High
2/14/2018Northland SecuritiesReiterated RatingBuy$6.00Medium
11/10/2017Piper Jaffray CompaniesReiterated RatingBuy$12.00N/A
9/26/2017Northland SecuritiesReiterated RatingBuy$13.00Low
7/26/2017Piper Jaffray CompaniesReiterated RatingBuy$10.00High
6/13/2017Northland SecuritiesSet Price TargetBuy$13.00High
5/23/2017William BlairReiterated RatingBuyLow
5/16/2017Northland SecuritiesReiterated RatingBuy$13.00Low
5/8/2017Northland SecuritiesReiterated RatingBuy$13.00Low
4/27/2017Stifel NicolausReiterated RatingBuy ➝ Buy$9.00 ➝ $10.00High
4/23/2017Northland SecuritiesReiterated RatingOutperform$13.00Medium
2/15/2017Stifel NicolausReiterated RatingBuy$8.00 ➝ $9.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Invuity logo
Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Read More

Today's Range

Now: $7.39
Low: $7.39
High: $7.39

50 Day Range

MA: N/A

52 Week Range

Now: $7.39
Low: $2.35
High: $9.55

Volume

N/A

Average Volume

324,995 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Invuity?

The following Wall Street research analysts have issued research reports on Invuity in the last twelve months:
View the latest analyst ratings for IVTY.

What is the current price target for Invuity?

0 Wall Street analysts have set twelve-month price targets for Invuity in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Invuity in the next year.
View the latest price targets for IVTY.

What is the current consensus analyst rating for Invuity?

Invuity currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IVTY.

How do I contact Invuity's investor relations team?

Invuity's physical mailing address is 444 DE HARO STREET, San Francisco CA, 94107. The medical instruments supplier's listed phone number is 415-655-2100 and its investor relations email address is [email protected] The official website for Invuity is www.invuity.com.